Trials / Completed
CompletedNCT00273390
A Clinical Trial of Infliximab for Uveitis
The Use of Remicade (Infliximab) in the Management of Vision-threatening Uveitis That is Refractory to Other Modes of Systemic Immunosuppression
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 32 (planned)
- Sponsor
- Oregon Health and Science University · Academic / Other
- Sex
- All
- Age
- 9 Years
- Healthy volunteers
- Not accepted
Summary
This project is designed to test the hypothesis that inhibition of binding between tumor necrosis factor alpha (TNF-alpha) and its receptors using Remicade (infliximab, chimeric mouse/human IgG1K monoclonal antibody directed against human TNF-alpha, Centocor, Malvern,PA) is clinically useful for patients with uveitis that is refractory to other forms of systemic immunosuppressive therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Remicade (infliximab) |
Timeline
- Start date
- 2001-08-01
- Primary completion
- 2006-12-01
- Completion
- 2006-12-01
- First posted
- 2006-01-09
- Last updated
- 2011-07-04
Source: ClinicalTrials.gov record NCT00273390. Inclusion in this directory is not an endorsement.